Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  everolimus
Find trials that include:  Any drugs shown
Results 1-25 of 55 for your search:
Start Over
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Status: Active
Phase: Phase IV
Type: Treatment
Age: Any age
Trial IDs: CRAD001C2X01B, NCI-2013-01151, NCT01789281
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, S1207/NSABP B-53, SWOG-S1207, NCT01674140
Everolimus and Sorafenib Tosylate in Treating Patients with Recurrent High-Grade Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0011, NCI-2015-02100, BTTC09-01, P152430, NCT01434602
Phase Ib/II trial using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer with CNS Metastasis
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TRIO-US B09, NCI-2013-00082, 12-001358-CR-00003, CRAD001JUS182T, NCT01783756
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients with Pancreatic Neuroendocrine Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201303150, NCI-2013-00641, NCT01784861
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2106, NCI-2013-01630, NCT01857193
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RX-0201-P2-A-09, NCI-2014-02443, NCT02089334
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011XUS29, NCI-2016-00995, NCT02732119
Everolimus Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-23409, NCI-2012-00764, 06-08-20-01, NCT00831480
Everolimus and Panobinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: Pro00012947, NCI-2013-02164, NCT00978432
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Lapatinib Ditosylate and Everolimus in Treating Patients with HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2010-IIT-Novartis-RAD-001, NCI-2016-00027, HSC 12418, NCT01283789
Everolimus, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Progressive HER2-Positive Breast Cancer and Brain Metastases
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: LCCC 1025, NCI-2013-01079, 11-0242, NCT01305941
GSK1120212 Rollover Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Everolimus and Bevacizumab in Treating Patients with Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-226, NCI-2011-01944, NCT01399918
Everolimus in Treating Vestibular Schwannoma in Patients with Neurofibromatosis Type 2
Status: Active
Phase: Phase II
Type: Treatment
Age: 16 to 65
Trial IDs: 13-001492, NCI-2015-01455, NCI-2015-01443, NCT01345136
Rituximab and Everolimus in Treating Patients with B-Cell Lymphoma, Gray Zone Lymphoma, or Hodgkin Lymphoma Receiving High-Dose Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: J1228, NCI-2012-02757, CIR00004190, CRAD001NUS157T, NA_00067315, NCT01665768
Everolimus in Treating Younger Patients With Recurrent or Progressive Low-Grade Gliomas
Status: Active
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Age: 3 to 21
Trial IDs: 120817, NCI-2012-02774, PNOC001, NCT01734512
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9149, NCI-2013-01588, 130105, MPACT, P121047, 13-C-0105, NCT01827384
Everolimus With or Without Temozolomide in Treating Patients With Newly-Diagnosed Low-Grade Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 131012, NCI-2014-00749, 081184, CRAD001CUS225T, NCT02023905
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BRE12-158, NCI-2015-00307, NCT02101385
Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091302, NCI-2014-00623, NCT02143726
Start Over